iMedicor today announced it has signed an agreement with Dallas-based Access Pharmaceuticals for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.
IMedicor signs agreement with Access Pharmaceuticals for the North American commercial launch of MuGard